Vyjuvek™ (beremagene geperpavec-svdt)

EviCore covers Vyjuvek for topical treatment of one or more open wounds in patients ≥6 months with dystrophic epidermolysis bullosa who have a documented pathogenic COL7A1 mutation, at least one DEB clinical feature, and a target wound that is clean, adequately granulated/vascularized and confirmed free of squamous cell carcinoma; it is excluded for patients <6 months, infected wounds, wounds lacking adequate granulation/vascularization, wounds with SCC, or when genetic confirmation or specialist prescribing/consultation is absent. Key requirements are prescribing by or consult with a dermatologist or wound care specialist, documentation of genetic testing, wound assessments and measurements, once-weekly application with age-based PFU/volume caps (6 mo–<3 yr: 1.6×10^9 PFU/0.8 mL; ≥3 yr: 3.2×10^9 PFU/1.6 mL), and initial/renewal approvals limited to 6 months with reauthorization only if the same target wound remains open and has decreased in size from baseline.